MedWatch

Brazilian success: SynAct Pharma scores positive results with therapy for covid-19

After generating promising results in a phase II trial with the company's anti-inflammatory drug for treating covid-19, SynAct Pharma is looking into the possibility of launching phase III.

Photo: Pilar Olivares/Reuters/Ritzau Scanpix

SynAct Pharma has received encouraging results from the clinical trial which the company launched in April earlier this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs